Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a ...

Patient education conversations emphasize 3 core elements: equivalent efficacy supported by rigorous pharmacokinetic and ...

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment ...

Kelly Preti, DNP, MBA, AGACNP-BC, OCN, PMGT-BC, is an adult-gerontology acute care nurse practitioner and APP education specialist within Memorial Sloan Kettering Cancer Center’s anesthesia pain ...

A patient with breast cancer was able to avoid unnecessary mastectomy through the use of a virtual reality simulation, ...

BCMA-targeting ADC belantamab mafodotin was approved for use in patients with relapsed/refractory multiple myeloma after 2 or more lines of treatment. Belantamab mafodotin-blmf (Blenrep) has been ...

Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC. The addition of lenvatinib (Lenvima) to ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...